When Standard Oncology Pathways Reach Their Limit
An independent, evidence-based intelligence platform helping physicians navigate advanced treatment options for patients who have exhausted standard care — across 8 countries and 200+ partner institutions.
The Reality Check
Myth: "A medical coordination company will manage your patient's treatment and guarantee a cure."
Reality: We provide the logistical roadmap, cost transparency, and hospital introductions. You and your licensed physician colleagues make all medical decisions. We do not guarantee outcomes, we never collect sensitive medical data on this website, and our role ends once you are directly connected to the partner center.
Three Clinical Decision Support Services
Structured, evidence-based intelligence for referring physicians — at no cost.
Treatment Pathway Navigation
When local guidelines have been exhausted, we map the patient's molecular profile, prior treatments, and clinical status to available therapies across our global network.
- Matches cases to available institutions
- Country-specific access conditions
- Transparent cost estimates from multiple centers
- Travel, visa, accommodation logistics
- Referring physician oversight maintained
- Post-treatment continuity coordination
International Tumor Board
Submit de-identified cases for evaluation by 2–3 independent specialist oncologists. Structured consensus recommendation with PubMed citations within 48–72 hours.
- 2–3 independent specialist opinions per case
- Consensus-based methodology (reduced bias)
- Structured recommendation document
- Clinical trial eligibility assessment
- Multi-country treatment landscape view
- Optional physician-to-physician consultation
Global Trial Intelligence
Real-time intelligence on clinical trial availability, feasibility, eligibility, and enrollment conditions — including one of the world's largest CAR-T trial ecosystems.
- 700+ CAR-T trials in China alone
- Trials across 8 countries
- Eligibility criteria matching
- Real-time slot availability verification
- Next-generation constructs (dual-target, allogeneic)
- Enrollment coordination support
Areas of Highest Expertise
Our global network covers a wide range of therapeutic modalities, targets, and cancer types.
Therapeutic Modalities
- CAR‑T Cell Therapy (CD19, BCMA, CD22, dual-target)
- Bispecific Antibodies (CD3/CD20, BCMA/CD3)
- TIL Therapy
- Gamma Delta T‑Cell Therapy
- NK Cell Therapy
- Antibody-Drug Conjugates (ADCs)
- Checkpoint Inhibitors & Combinations
- Personalized Cancer Vaccines
Rare & Emerging Targets
- GPC3 (Hepatocellular Carcinoma)
- Claudin18.2 (Gastric, Pancreatic)
- Mesothelin (Mesothelioma, Ovarian)
- GD2 (Neuroblastoma, Sarcoma)
- EGFRvIII (Glioblastoma)
- MUC1, MUC16 (Ovarian, Pancreatic)
- NY-ESO-1 (Sarcoma, Melanoma)
- MAGE-A4 (Multiple Solid Tumors)
Cancer Types
- DLBCL, ALL, AML, Multiple Myeloma
- Mantle Cell Lymphoma, Follicular Lymphoma
- Lung Cancer (NSCLC & SCLC)
- Pancreatic Cancer
- Gastric / Gastroesophageal Cancer
- Liver Cancer (HCC)
- Colorectal Cancer
- Glioblastoma
- Triple‑Negative Breast Cancer
- Sarcoma & Rare Solid Tumors
Google / PubMed vs CancerCareE
What you can find through literature search — and what we provide that you cannot easily collect yourself.
Google / PubMed
- Published clinical trial data (often years old)
- Single-center outcomes
- Regulatory approvals (time‑lagged)
- Abstract‑level information only
- No real‑time slot availability
- No logistical feasibility data
- Patient advocacy content
CancerCareE
- Aggregated real‑world outcomes (anonymized)
- Multi‑center, multi‑country data
- Regulatory conditions — country‑specific
- Full protocol and access conditions
- Real‑time manufacturing slot verification
- Visas, accommodation, language support
- Independent, evidence‑based intelligence
Intelligence You Cannot Easily Collect Yourself
Data that is not available in PubMed, clinical trial registries, or hospital websites.
Case Stories
Three documented cases demonstrating how pathway intelligence works in practice.
Case 1: Relapsed DLBCL After Second-Line Therapy
Prior Therapies: R‑CHOP ×6, R‑ICE ×3 — progressive disease
Molecular Finding: CD19‑positive, adequate organ function
Review Outcome: Dual‑target CD19/CD22 CAR‑T study (Shanghai)
Center: Academic medical center, 14‑day vein‑to‑vein time
Case 2: Advanced HCC with GPC3 Expression
Prior Therapies: Sorafenib → progression at 4 months. Lenvatinib → progression at 6 months
Molecular Finding: GPC3‑positive by IHC. Child‑Pugh A. ECOG 1.
Review Outcome: GPC3‑targeted CAR‑T phase I/II study
Selected Country: China — GPC3 CAR‑T not available in home country
Case 3: Metastatic Gastric Cancer — CLDN18.2 Positive
Prior Therapies: FOLFOX → progression. Ramucirumab + paclitaxel → progression
Molecular Finding: Claudin18.2 (IHC 2+, >70% tumor cells). HER2‑negative. MSI‑stable.
Review Outcome: Claudin18.2‑targeted CAR‑T clinical study
Selected Center: Beijing — one of world's most experienced in CLDN18.2 CAR‑T
Why China Matters for Advanced Cell Therapy
Documented facts about one of the world's largest clinical trial ecosystems.
Counter‑Signal: What China Is Not
We do not promote China as the only destination. We document access conditions across all 8 countries in our network. China is not a "cheap alternative" — it is a high‑volume clinical trial ecosystem with 700+ active studies.
- Not every therapy is available in China
- Not every patient is eligible for Chinese trials
- We do not claim China is "the best" — we document what exists
Security & Data Protection
We take data security and patient privacy seriously.
How Is This Service Funded?
CancerCareE is completely free for physicians and patients to use for information and introduction services.
After a patient is introduced to a partner institution, CancerCareE may receive a fixed referral fee from the partner center.
This fee is not performance‑based and does not influence which center is suggested. Our recommendations are based on clinical trial availability, hospital accreditation, and treatment protocols.
Who Can Use This Service?
✓ Eligible Physicians
- Board‑certified oncologists (medical, radiation, surgical)
- Board‑certified hematologists
- Active, unrestricted medical license
- Verified institutional affiliation
- Specialists in cellular therapy or immunotherapy
- Physicians treating rare or complex cancers
- Academic researchers in oncology
- Clinical trial investigators
✗ Not Eligible
- Non‑licensed practitioners
- Physicians with restricted or suspended licenses
- Alternative medicine providers without oncology certification
- Unverified institutional affiliations
- Commercial entities seeking patient data
- Individuals misrepresenting credentials
How to Get Started
A simple, structured process for referring physicians.
Submit Credentials
Complete physician verification form
Verification
License, board certification, affiliation validation (24‑48h)
Submit Patient Case
Upload de‑identified case for review
Receive Recommendation
Structured pathway within 48‑72h
Our Global Network
Partner institutions across 8 countries, each with therapy-specific experience.
Network continuously expanding. Data current as of August 2026.
Frequently Asked Questions
CancerCareE provides physicians with access to advanced treatment pathways, international tumor board reviews, and clinical trial intelligence across 8 countries — all at no cost.
CancerCareE is funded through fixed referral fees from partner institutions after patient introduction. This does not influence clinical recommendations or referral choices.
We provide real-world data on response rates, manufacturing timelines, regulatory conditions, hospital experience, and trial slot availability — intelligence not found in PubMed.
All submissions are de-identified. Data is encrypted at rest and in transit. Role-based access with MFA. HIPAA-aligned and GDPR-ready. PHI is not stored longer than necessary.
CancerCareE is an independent information and introduction platform — not a healthcare provider. We provide pathway intelligence and connect physicians to partner institutions.
Ready to Explore Options for Your Patient?
Get independent, evidence-based pathway intelligence for your patient — at no cost.
Explore Related Clinical Intelligence
Cross-reference with our evidence-based resources.
Therapy Intelligence
Deep-dive technical comparisons of CAR‑T, TIL, NK, and Gamma Delta
Clinical Trials Database
700+ active CAR‑T trials with NCT numbers and eligibility
Response Rate Database
PubMed‑cited ORR, CR, PFS, OS data
Independent Medical Advisors
Meet the specialists in our international tumor board